NEW YORK – Hutchmed on Wednesday said it started a Phase I/IIa trial of its antibody-targeted therapy conjugate (ATTC) HMPL-A580 in patients with unresectable, advanced or metastatic solid tumors.
A BridgeBio Pharma drug developed for dwarfism increased children’s growth rates in a pivotal clinical trial, meeting the study’s main goal and boosting the daily pill’s chances to offer an ...
Tyra Biosciences Inc. has disclosed new indazole compounds acting as fibroblast growth factor receptor (FGFR) inhibitors. They are reported to be useful for the treatment of cancer and developmental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results